Entries by Doreen M. Rachal

17 06 '26

China’s New Supply Chain Security Regulations: Key Takeaways for Companies With China Operations or China-Linked Supply Chains

/in , , /by

China’s new Regulations on Industrial and Supply Chain Security, which took effect on April 7, 2026, add another significant layer to the country’s expanding countermeasures framework. The regulations give Chinese authorities broad powers to monitor activities that could be viewed as threatening China’s industrial or supply chain security, creating new compliance challenges for companies with China operations or China-linked supply chains.

From increased scrutiny of key sectors and supply chain due diligence to heightened risks around supplier transitions, customer terminations, and sanctions-driven business decisions, the regulations underscore a growing reality: actions taken to comply with foreign trade restrictions may carry legal consequences in China.

In this blog post, we examine the regulations’ key provisions, identify four principal risk areas for multinational companies, and discuss practical steps companies should consider as conflict-of-laws risks become increasingly difficult to avoid.

26 05 '26

DOJ and Texas AG Announce First Settlement in National Investigation of Gender-Affirming Care for Minors

/in , , , , /by

On May 15, 2026, the U.S. Department of Justice and the Texas Attorney General announced the first publicly disclosed settlement arising from the federal government’s nationwide investigation into gender-affirming care for minors. The resolution with Texas Children’s Hospital reflects a coordinated federal-state enforcement approach grounded in False Claims Act (“FCA”) and Federal Food, Drug, and Cosmetic Act (“FDCA”) theories, alongside significant non-monetary remedies extending beyond traditional healthcare fraud settlements. In addition to a substantial monetary payment, the agreements impose operational, clinical, and governance-related obligations that may signal how enforcement authorities intend to pursue similar matters going forward.

This blog post examines the settlement terms, the broader federal policy and enforcement framework underlying the investigation, and the implications for healthcare providers and life sciences companies navigating areas of aligned federal and state enforcement focus. Click to read more about the resolution and what it may signal for future DOJ and state attorney general enforcement activity.